Nucl Med Mol Imaging.  2017 Mar;51(1):58-68. 10.1007/s13139-016-0461-6.

¹⁸F-FDG PET/CT for the Diagnosis of Malignant and Infectious Complications After Solid Organ Transplantation

Affiliations
  • 1Biophysics and Nuclear Medicine, Hautepierre Hospital, University Hospitals of Strasbourg, 1 Avenue Molière, Strasbourg 67200, France. nastassja.muller@gmail.com
  • 2Department of Nuclear Medicine, Haguenau Hospital, 64, avenue Prof. Rene Leriche, BP 40252, Haguenau 67504, France.
  • 3Pneumology, Nouvel Hôpital Civil, University Hospitals of Strasbourg, 1 Place de l'hôpital, Strasbourg 67000, France.
  • 4EA 7293 Vascular and Tissular Stress in Transplantation and FMTS, Faculty of Medicine, Strasbourg, France.
  • 5Nephrology, Nouvel Hôpital Civil, University Hospitals of Strasbourg, 1 Avenue Molière, Strasbourg 67200, France.
  • 6Cardiology, Nouvel Hôpital Civil, University Hospitals of Strasbourg, 1 Place de l'hôpital, Strasbourg 67000, France.
  • 7ICube, University of Strasbourg/CNRS (UMR 7357) and FMTS, Faculty of Medicine, Strasbourg, France.
  • 8Oncology and Hematology, Hautepierre Hospital, University Hospitals of Strasbourg, 1 Avenue Molière, Strasbourg 67200, France.

Abstract

PURPOSE
Infection and malignancy represent two common complications after solid organ transplantation, which are often characterized by poorly specific clinical symptomatology. Herein, we have evaluated the role of 18F-fluoro-2-deoxy-Dglucose (FDG) positron emission tomography/computed tomography (PET/CT) in this clinical setting.
METHODS
Fifty-eight consecutive patients who underwent FDG PET/CT after kidney, lung or heart transplantation were included in this retrospective analysis. Twelve patients underwent FDGPET/CT to strengthen or confirma diagnostic suspicion of malignancies. The remaining 46 patients presented with unexplained inflammatory syndrome, fever of unknown origin (FUO), CMVor EBV seroconversion during post-transplant follow-up without conclusive conventional imaging. FDG PET/CT results were compared to histology or to the finding obtained during a clinical/imaging follow-up period of at least 6 months after PET/CT study.
RESULTS
Positive FDG PET/CT results were obtained in 18 (31 %) patients. In the remaining 40 (69 %) cases, FDG PET/CT was negative, showing exclusively a physiological radiotracer distribution. On the basis of a patient-based analysis, FDG PET/CT's sensitivity, specificity, PPV and NPV were respectively 78 %, 90 %, 78 % and 90 %, with a global accuracy of 86 %. FDG PET/CT was true positive in 14 patients with bacterial pneumonias (n = 4), pulmonary fungal infection (n = 1), histoplasmosis (n = 1), cutaneous abscess (n = 1), inflammatory disorder (sacroiliitis) (n = 1), lymphoma (n = 3) and NSCLC (n = 3). On the other hand, FDG PET/CT failed to detect lung bronchoalveolar adenocarcinoma, septicemia, endocarditis and graft-versus-host disease (GVHD), respectively, in four patients. FDG PET/CT contributed to adjusting the patient therapeutic strategy in 40 % of cases.
CONCLUSIONS
FDG PET/CT emerges as a valuable technique to manage complications in the post-transplantation period. FDG PET/CT should be considered in patients with severe unexplained inflammatory syndrome or FUO and inconclusive conventional imaging or to discriminate active from silent lesions previously detected by conventional imaging particularly when malignancy is suspected.

Keyword

FDG; PET; Organ transplantation; Post-transplant lymphoproliferative disorders; Post-transplant complication; Infection

MeSH Terms

Abscess
Adenocarcinoma
Diagnosis*
Electrons
Endocarditis
Fever of Unknown Origin
Follow-Up Studies
Graft vs Host Disease
Hand
Heart Transplantation
Herpesvirus 4, Human
Histoplasmosis
Humans
Kidney
Lung
Lung Diseases, Fungal
Lymphoma
Organ Transplantation*
Pneumonia, Bacterial
Positron-Emission Tomography and Computed Tomography*
Retrospective Studies
Sensitivity and Specificity
Sepsis
Seroconversion
Transplants*
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr